SG11202011704XA - Glp-1 receptor agonists and uses thereof - Google Patents
Glp-1 receptor agonists and uses thereofInfo
- Publication number
- SG11202011704XA SG11202011704XA SG11202011704XA SG11202011704XA SG11202011704XA SG 11202011704X A SG11202011704X A SG 11202011704XA SG 11202011704X A SG11202011704X A SG 11202011704XA SG 11202011704X A SG11202011704X A SG 11202011704XA SG 11202011704X A SG11202011704X A SG 11202011704XA
- Authority
- SG
- Singapore
- Prior art keywords
- glp
- receptor agonists
- agonists
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862685656P | 2018-06-15 | 2018-06-15 | |
PCT/IB2019/054961 WO2019239371A1 (fr) | 2018-06-15 | 2019-06-13 | Agonistes du récepteur glp-1 et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011704XA true SG11202011704XA (en) | 2020-12-30 |
Family
ID=67766191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011704XA SG11202011704XA (en) | 2018-06-15 | 2019-06-13 | Glp-1 receptor agonists and uses thereof |
Country Status (21)
Country | Link |
---|---|
US (2) | US11858916B2 (fr) |
EP (1) | EP3806855B1 (fr) |
JP (1) | JP7053900B2 (fr) |
KR (1) | KR102538572B1 (fr) |
CN (1) | CN112566637B (fr) |
AU (1) | AU2019285570B2 (fr) |
BR (1) | BR112020024956A2 (fr) |
CA (1) | CA3103051C (fr) |
DK (1) | DK3806855T5 (fr) |
ES (1) | ES2943510T3 (fr) |
FI (1) | FI3806855T3 (fr) |
HU (1) | HUE061888T2 (fr) |
IL (1) | IL279224B2 (fr) |
MX (1) | MX2020013624A (fr) |
PL (1) | PL3806855T3 (fr) |
PT (1) | PT3806855T (fr) |
RU (1) | RU2765721C1 (fr) |
SG (1) | SG11202011704XA (fr) |
SI (1) | SI3806855T1 (fr) |
WO (1) | WO2019239371A1 (fr) |
ZA (1) | ZA202007304B (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU20210042A7 (es) | 2018-11-22 | 2022-01-13 | Qilu Regor Therapeutics Inc | Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
MA55627A (fr) * | 2019-04-12 | 2022-02-16 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
WO2021018023A1 (fr) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | Modulateur du récepteur glp-1 à petites molécules |
CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
JP2023513272A (ja) | 2020-02-07 | 2023-03-30 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
JP2023515404A (ja) * | 2020-02-13 | 2023-04-13 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
IL296336A (en) * | 2020-03-18 | 2022-11-01 | Lg Chemical Ltd | A agonist for the glp-1 receptor, a pharmaceutical preparation containing it and a method for its preparation |
TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
CN113493447B (zh) * | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
JP2023523176A (ja) * | 2020-04-22 | 2023-06-02 | アニマ バイオテック インコーポレイテッド | コラーゲン1翻訳阻害剤及びその使用方法 |
JP2023524493A (ja) * | 2020-04-29 | 2023-06-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
NZ796075A (en) * | 2020-06-04 | 2023-04-28 | Hangzhou Sciwind Biosciences Co Ltd | Five-membered heteroaromatic imidazole compound and use thereof |
EP4166142A4 (fr) * | 2020-06-10 | 2024-06-26 | Medshine Discovery Inc | Composé de benzobisoxazole à substitution méthyle et son utilisation |
CN115916772A (zh) * | 2020-06-19 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
CN113816948B (zh) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
CN113831337B (zh) * | 2020-06-24 | 2023-03-24 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
MX2023001311A (es) | 2020-08-06 | 2023-04-18 | Gasherbrum Bio Inc | Agonistas heterociclicos de glp-1. |
WO2022040600A1 (fr) * | 2020-08-21 | 2022-02-24 | Terns Pharmaceuticals, Inc. | Composés en tant qu'agonistes de glp-1r |
CN116406360A (zh) * | 2020-08-28 | 2023-07-07 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
WO2022068772A1 (fr) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale |
CN116547279A (zh) * | 2020-10-13 | 2023-08-04 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
US20240083886A1 (en) * | 2020-10-13 | 2024-03-14 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
CN114478497B (zh) * | 2020-11-12 | 2023-10-20 | 杭州中美华东制药有限公司 | 芳基烷基酸类glp-1受体激动剂及其用途 |
US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
CA3200245A1 (fr) | 2020-11-27 | 2022-06-02 | Junjun Wu | Derive de benzimidazole, son procede de preparation et son utilisation medicale |
CN114591308B (zh) | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | 一类glp-1r受体激动剂化合物及其用途 |
WO2022184849A1 (fr) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Agonistes de glp-1r, utilisations et compositions pharmaceutiques associées |
WO2022202864A1 (fr) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | Composition pharmaceutique contenant un agoniste du récepteur glp-1 comportant un cycle fusionné |
JP2024514259A (ja) * | 2021-04-08 | 2024-03-29 | エルジー・ケム・リミテッド | Glp-1受容体作動薬、それを含む薬学的組成物、およびその製造方法 |
KR20230173708A (ko) | 2021-04-21 | 2023-12-27 | 길리애드 사이언시즈, 인코포레이티드 | 카르복시-벤즈이미다졸 glp-1r 조절 화합물 |
WO2022246019A1 (fr) | 2021-05-20 | 2022-11-24 | Eli Lilly And Company | Agonistes macrocycliques du récepteur du peptide 1 de type glucagon |
CN117715906A (zh) * | 2021-07-21 | 2024-03-15 | 和博医药有限公司 | 胰高血糖素样肽-1受体调节剂及其用途 |
CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
TW202321240A (zh) * | 2021-08-02 | 2023-06-01 | 大陸商深圳信立泰藥業股份有限公司 | Glp-1r促效劑化合物的鹽、包括其的藥物組合物及其用途 |
KR20240042624A (ko) * | 2021-08-04 | 2024-04-02 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 시클로알켄계 유도체 조절제, 이의 제조 방법 및 응용 |
CN118215478A (zh) | 2021-09-08 | 2024-06-18 | 盐野义制药株式会社 | 用于预防和治疗与抗肥胖作用有关的疾病的药物 |
WO2023057414A1 (fr) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certaines octahydrofuro 3,4-b]pyrazines utilisées en tant que modulateurs du récepteur glp-1 |
CA3233131A1 (fr) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certains 2,5-diazabicyclo[4.2.0]octanes utilises en tant que modulateurs du recepteur glp-1 |
WO2023057429A1 (fr) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certains 2,5-diazabicyclo[4.2.0]octanes et octahydrofuro[3,4-b]pyrazines utilisés en tant que modulateurs du récepteur glp-1 |
WO2023066356A1 (fr) * | 2021-10-22 | 2023-04-27 | 盛世泰科生物医药技术(苏州)有限公司 | Composé utilisé en tant qu'agoniste du récepteur glp-1 et son utilisation |
CN115850296A (zh) * | 2021-12-03 | 2023-03-28 | 杭州先为达生物科技有限公司 | 一种噻吩并咪唑类化合物的晶型及其制备方法 |
WO2023111144A1 (fr) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | 3-azabicyclo [3.1.0] hexanes en tant que modulateurs du récepteur glp-1 |
WO2023111145A1 (fr) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certains 3-azabicyclo[3.1.0] hexanes utilisés en tant que modulateurs du récepteur de glp-1 |
WO2023130878A1 (fr) * | 2022-01-10 | 2023-07-13 | 海思科医药集团股份有限公司 | Sel agoniste du glp-1, et forme cristalline et utilisation médicale de celui-ci |
WO2023138684A1 (fr) * | 2022-01-24 | 2023-07-27 | Gasherbrum Bio , Inc. | Agonistes hétérocycliques de glp-1 |
US20230322758A1 (en) | 2022-02-23 | 2023-10-12 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
WO2023169436A1 (fr) * | 2022-03-08 | 2023-09-14 | 广州市联瑞制药有限公司 | Composé benzo bicyclique, son procédé de préparation et son application |
WO2024026338A1 (fr) * | 2022-07-27 | 2024-02-01 | Carmot Therapeutics, Inc. | Agonistes du récepteur rcpg n-hétérocylique, compositions pharmaceutiques les comprenant et leurs procédés d'utilisation |
WO2024102625A1 (fr) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Agonistes de récepteur du peptide 1 de type glucagon |
WO2024107781A1 (fr) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Agonistes du récepteur du glucagon-like peptide 1 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US20040127504A1 (en) * | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
RU2006126122A (ru) | 2003-12-19 | 2008-01-27 | Бристол-Маерс Сквибб Компани (Us) | Азабициклические гетероциклы как модуляторы каннабиоидного рецептора |
EP2004613A2 (fr) | 2006-03-31 | 2008-12-24 | AstraZeneca AB | Composés de benzimidazole bicyclique et leur utilisation comme potentialisateurs du récepteur métabotropique du glutamate |
CN103221404B (zh) * | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
HUE031733T2 (en) * | 2012-09-21 | 2017-07-28 | Sanofi Sa | Benzimidazole carboxylic acid amide derivatives for the treatment of metabolic or cardiovascular diseases |
PE20191501A1 (es) | 2016-12-16 | 2019-10-22 | Pfizer | Agonistas receptores de glp-1 y sus usos de los mismos |
TWI707683B (zh) | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Glp-1受體促效劑及其用途 |
CU20210042A7 (es) * | 2018-11-22 | 2022-01-13 | Qilu Regor Therapeutics Inc | Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen |
-
2019
- 2019-06-13 PT PT197590276T patent/PT3806855T/pt unknown
- 2019-06-13 SI SI201930518T patent/SI3806855T1/sl unknown
- 2019-06-13 US US17/251,929 patent/US11858916B2/en active Active
- 2019-06-13 WO PCT/IB2019/054961 patent/WO2019239371A1/fr active Application Filing
- 2019-06-13 FI FIEP19759027.6T patent/FI3806855T3/fi active
- 2019-06-13 EP EP19759027.6A patent/EP3806855B1/fr active Active
- 2019-06-13 DK DK19759027.6T patent/DK3806855T5/da active
- 2019-06-13 SG SG11202011704XA patent/SG11202011704XA/en unknown
- 2019-06-13 AU AU2019285570A patent/AU2019285570B2/en active Active
- 2019-06-13 PL PL19759027.6T patent/PL3806855T3/pl unknown
- 2019-06-13 JP JP2020569823A patent/JP7053900B2/ja active Active
- 2019-06-13 ES ES19759027T patent/ES2943510T3/es active Active
- 2019-06-13 RU RU2020141022A patent/RU2765721C1/ru active
- 2019-06-13 KR KR1020217000887A patent/KR102538572B1/ko active IP Right Grant
- 2019-06-13 HU HUE19759027A patent/HUE061888T2/hu unknown
- 2019-06-13 MX MX2020013624A patent/MX2020013624A/es unknown
- 2019-06-13 CN CN201980053998.2A patent/CN112566637B/zh active Active
- 2019-06-13 BR BR112020024956-4A patent/BR112020024956A2/pt unknown
- 2019-06-13 CA CA3103051A patent/CA3103051C/fr active Active
-
2020
- 2020-11-24 ZA ZA2020/07304A patent/ZA202007304B/en unknown
- 2020-12-06 IL IL279224A patent/IL279224B2/en unknown
-
2023
- 2023-11-20 US US18/513,752 patent/US20240132483A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL279224B2 (en) | 2023-07-01 |
HUE061888T2 (hu) | 2023-08-28 |
KR102538572B1 (ko) | 2023-06-01 |
US20210332034A1 (en) | 2021-10-28 |
EP3806855A1 (fr) | 2021-04-21 |
US11858916B2 (en) | 2024-01-02 |
RU2765721C1 (ru) | 2022-02-02 |
AU2019285570B2 (en) | 2022-03-24 |
PL3806855T3 (pl) | 2023-07-24 |
IL279224A (en) | 2021-01-31 |
MX2020013624A (es) | 2022-08-11 |
IL279224B1 (en) | 2023-03-01 |
CA3103051A1 (fr) | 2019-12-19 |
BR112020024956A2 (pt) | 2021-03-09 |
JP7053900B2 (ja) | 2022-04-12 |
CA3103051C (fr) | 2023-01-17 |
ZA202007304B (en) | 2023-11-29 |
AU2019285570A1 (en) | 2020-12-17 |
PT3806855T (pt) | 2023-05-03 |
WO2019239371A1 (fr) | 2019-12-19 |
DK3806855T3 (da) | 2023-04-24 |
EP3806855B1 (fr) | 2023-03-01 |
FI3806855T3 (fi) | 2023-05-04 |
KR20210020095A (ko) | 2021-02-23 |
DK3806855T5 (da) | 2023-05-22 |
ES2943510T3 (es) | 2023-06-13 |
CN112566637A (zh) | 2021-03-26 |
JP2021528394A (ja) | 2021-10-21 |
US20240132483A1 (en) | 2024-04-25 |
SI3806855T1 (sl) | 2023-06-30 |
CN112566637B (zh) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279300A (en) | 1-GLP agonist receptors and their use | |
IL279224B1 (en) | 1-glp agonist receptors and their use | |
ZA201904616B (en) | Glp-1 receptor agonists and uses thereof | |
IL283322A (en) | glp-1r agonists and uses thereof | |
EP3807267A4 (fr) | Agonistes du récepteur de l'hormone thyroïdienne et utilisations associées | |
EP4058445A4 (fr) | Agoniste du récepteur glp-1 et son utilisation | |
IL281475A (en) | Paranoid X receptor agonists and uses thereof | |
EP3463429A4 (fr) | Agonistes partiels du récepteur de l'insuline et analogues du glp-1 | |
IL281471A (en) | Farnesoid x receptor agonists and uses thereof | |
IL281474A (en) | Farnesoid x receptor agonists and uses thereof | |
IL304574A (en) | Glucagon-like peptide-1 receptor agonists and their uses | |
EP3445769A4 (fr) | Agoniste du récepteur des hormones thyroïdiennes et son utilisation | |
GB201811757D0 (en) | Composition comprising GLP-1 receptor agonist and glucagon receptor agonist and application thereof | |
ZA202209312B (en) | Glp-1r agonists and uses thereof | |
GB201817943D0 (en) | Galanin-2 receptor agonists | |
GB201816650D0 (en) | GLP-1 Receptor antagonists |